Citadel Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-10,500
| Closed | -$396K | – | 14984 |
|
|
2021
Q1 | $396K | Sell |
10,500
-20,600
| -66% | -$514K | ﹤0.01% | 10201 |
|
|
2020
Q4 | $529K | Buy |
+31,100
| New | +$390K | ﹤0.01% | 8049 |
|
|
2020
Q3 | – | Sell |
-16,500
| Closed | -$101K | – | 11062 |
|
|
2020
Q2 | $101K | Buy |
16,500
+5,200
| +46% | +$21.4K | ﹤0.01% | 8989 |
|
|
2020
Q1 | $26K | Buy |
+11,300
| New | +$48K | ﹤0.01% | 9239 |
|
|
2019
Q2 | – | Sell |
-28,900
| Closed | -$387K | – | 10161 |
|
|
2019
Q1 | $387K | Buy |
+28,900
| New | +$330K | ﹤0.01% | 7222 |
|
|
2018
Q4 | – | Sell |
-18,200
| Closed | -$253K | – | 10060 |
|
|
2018
Q3 | $253K | Buy |
+18,200
| New | +$271K | ﹤0.01% | 7858 |
|
|
2018
Q2 | – | Sell |
-15,900
| Closed | -$273K | – | 9485 |
|
|
2018
Q1 | $273K | Buy |
+15,900
| New | +$310K | ﹤0.01% | 6886 |
|
|
2017
Q4 | – | Sell |
-10,400
| Closed | -$425K | – | 8638 |
|
|
2017
Q3 | $425K | Sell |
10,400
-13,000
| -56% | -$408K | ﹤0.01% | 5558 |
|
|
2017
Q2 | $705K | Buy |
23,400
+500
| +2% | +$15.6K | ﹤0.01% | 4622 |
|
|
2017
Q1 | $828K | Buy |
22,900
+17,600
| +332% | +$776K | ﹤0.01% | 4277 |
|
|
2016
Q4 | $266K | Buy |
+5,300
| New | +$278K | ﹤0.01% | 5850 |
|
|
2016
Q3 | – | Sell |
-5,600
| Closed | -$232K | – | 7990 |
|
|
2016
Q2 | $232K | Sell |
5,600
-1,800
| -24% | -$78.3K | ﹤0.01% | 5612 |
|
|
2016
Q1 | $301K | Buy |
7,400
+6,600
| +825% | +$227K | ﹤0.01% | 5098 |
|
|
2015
Q4 | $33K | Buy |
+800
| New | +$26.8K | ﹤0.01% | 7610 |
|
Citadel Advisors's FPRX Position: Q1 2021 in Review
Citadel Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2021, closing a stake of 706,864 shares — an estimated $17.6M sold.
Citadel Advisors first reported a position in FPRX in Q3 2014 and held it in 19 quarters. The position peaked at $12M in Q4 2020. 147 funds tracked by Wall St. Rank hold FPRX as of Q1 2021.
- Citadel Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
- Citadel Advisors sold 706,864 Five Prime Therapeutics, Inc. shares in Q1 2021, an estimated $17.6M.
- Citadel Advisors first reported a position in Five Prime Therapeutics, Inc. in Q3 2014 and held it in 19 quarters.
- Citadel Advisors's Five Prime Therapeutics, Inc. position peaked at $12M in Q4 2020.
- 147 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2021.
Based on Citadel Advisors's 13F filing for Q1 2021, filed 17 May 2021.